Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidoflu

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

Related Keywords

California , United States , San Diego , Ohio , Russia , Cleveland , Ukraine , Edna Kaplan , Valentina Sciacca , Paula Schwartz , Matej Ondrus , Christian Wolf , Daniel Vitt , Jessica Breu , Andreas Muehler , Robertj Fox , Mellen Center , Americas Committee For Treatment , Rx Communications Group , Prnewswire Immunic Inc , Nasdaq , Exchange Commission , Neurologic Institute , Research In Multiple Sclerosis , Immunic Inc , Low Rate , Confirmed Disability Worsening , Over Time , Compares Favorably , Historical Trial Data , Currently Available Multiple Sclerosis Treatments , Staff Neurologist , Multiple Sclerosis , Cleveland Clinic , Americas Committee , Coordinating Investigator , Chief Executive Officer , Poster Session , Vidofludimus Calcium , Private Securities Litigation Reform Act , Annual Report , Investor Relations , Immunic , Nc ,